Your browser doesn't support javascript.
loading
Estimating the Effectiveness of Kidney Cancer Screening Within Lung Cancer Screening Programmes: A Validation in UK Biobank.
Harrison, Hannah; Wood, Angela; Pennells, Lisa; Rossi, Sabrina H; Callister, Matthew; Cartledge, Jon; Stewart, Grant D; Usher-Smith, Juliet A.
Afiliación
  • Harrison H; Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Electronic address: hh504@medschl.cam.ac.uk.
  • Wood A; Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Pennells L; Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Rossi SH; Department of Surgery, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Callister M; Department of Respiratory Medicine, Leeds Teaching Hospitals Trust, Leeds, UK.
  • Cartledge J; St James University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Stewart GD; Department of Surgery, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Usher-Smith JA; Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Eur Urol Oncol ; 6(3): 351-353, 2023 06.
Article en En | MEDLINE | ID: mdl-37003861
In the absence of population-based screening, addition of screening for kidney cancer to lung cancer screening could provide an efficient and low-resource means to improve early detection. In this study, we used the UK Biobank cohort (n = 442 865) to determine the performance of the Yorkshire Lung Cancer Screening Trial (YLST) eligibility criteria for selecting individuals for kidney cancer screening. We measured the performance of two models widely used to determine eligibility for lung cancer screening (PLCO[m2012] and the Liverpool-Lung-Project-v2) and the performance of the combined YLST criteria. We found that the lung cancer models have discrimination (area under the receiver operating curve) between 0.60 and 0.68 for kidney cancer. In the UK, one in four cases (25%) of kidney cancer cases is expected to occur in those eligible for lung cancer screening, and one case of kidney cancer detected for every 200 people invited to lung cancer screening. These results suggest that adding kidney cancer screening to lung cancer screening would be an effective strategy to improve early detection rates of kidney cancer. However, most kidney cancers would not be picked up by this approach. This analysis does not address other important considerations about kidney cancer screening, such as overdiagnosis. PATIENT SUMMARY: It has been proposed that adding-on kidney cancer screening to lung cancer screening (both carried out by a computed tomography scan of the chest/abdomen) would be an easy and low-cost way of detecting cases of kidney cancer earlier, when these can be treated more easily. Lung cancer screening is usually targeted at people who are at a high risk (eg, older smokers); therefore, here we look at whether the same group of people are also at a high risk of kidney cancer. Our analysis shows that one in four people later diagnosed with kidney cancer are also at a high risk of lung cancer; hence, a combined screening programme could detect up to a quarter of kidney cancers.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies / Evaluation_studies / Prognostic_studies / Screening_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Eur Urol Oncol Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies / Evaluation_studies / Prognostic_studies / Screening_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Eur Urol Oncol Año: 2023 Tipo del documento: Article